Doctor of Dentistry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Zuniga

Dentist, Oral and Maxillofacial Surgery Dallas, TX Doctor of Dentistry

NPI 1588660856 CMS profile 162742

Oral And Maxillofacial Surgery, 5939 Harry Hines Blvd, #210, Dallas, TX 75390

Open in the dashboard

General payments

$60,660

99 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Zuniga of Dallas, TX is reported in the CMS Open Payments database as having received $60,660 across 99 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Dentist, Oral and Maxillofacial Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $797 10
2024 General $1,217 16
2023 General $1,068 13
2022 General $2,922 5
2021 General $10,025 9
2020 General $5,341 5
2019 General $39,290 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Zuniga
  • Dentist, Oral and Maxillofacial Surgery median
  • Middle half of Dentist, Oral and Maxillofacial Surgery
  • National median

In program year 2025, general payments to John Zuniga were reported at $797. Among 3,834 Dentist, Oral and Maxillofacial Surgery profiles paid that year, the median was $150 and the middle half received between $56 and $423.

Show as a table
Year John Zuniga Dentist, Oral and Maxillofacial Surgery median Middle half National median
2019 $39,290 $142 $50–$420 $163
2020 $5,341 $96 $36–$277 $114
2021 $10,025 $138 $45–$419 $132
2022 $2,922 $144 $48–$367 $149
2023 $1,068 $153 $55–$399 $160
2024 $1,217 $152 $50–$400 $164
2025 $797 $150 $56–$423 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AxoGen $58,425 72 payments
  2. KLS-Martin L.P. $1,320 11 payments
  3. Zimmer Biomet Holdings, Inc. $373 4 payments
  4. DePuy Synthes Sales Inc. $249 4 payments
  5. Checkpoint Surgical, Inc $145 2 payments
  6. Vertex Pharmaceuticals Incorporated $38 1 payment
  7. Integra LifeSciences Corporation $27 1 payment
  8. Straumann USA LLC $26 1 payment
  9. OraPharma, a division of Bausch Health US, LLC $24 1 payment
  10. Amgen Inc. $19 1 payment
  11. Other $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $30,829 6 payments
  2. Consulting Fee $18,025 5 payments
  3. Food and Beverage $8,177 80 payments
  4. Travel and Lodging $3,629 8 payments
Products named General payments · program years 2019–2025
  1. AxoGuard Nerve Connector $40,201 38 payments
  2. AXOGUARD NERVE PROTECTOR $40,201 38 payments
  3. Avance Nerve Graft $19,285 33 payments
  4. Axoguard HA+ Nerve Protector $460 8 payments
  5. AXOGUARD NERVE CAP $460 8 payments
  6. Walter $195 2 payments
  7. CMF Orthognathic $179 2 payments
  8. Checkpoint Stimulators $145 2 payments
  9. MATRIXMANDIBLE $121 1 payment
  10. TRUMATCH $101 2 payments
  11. Other $243 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

100

Median for Oral Surgery (Dentist only): 288

Drug cost

$1,988

Median for Oral Surgery (Dentist only): $1,122

Branded share of claims

27%

Median for Oral Surgery (Dentist only): 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Carbamazepine Generic 44 $1,477
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 27 $263
Gabapentin Generic 17 $227
Tizanidine Hcl Generic 12 $20

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,440 Part D prescribers listed as Oral Surgery (Dentist only); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$17,479

Medicare's payments for the services billed

Medicare patients

98

Average age 72

Services billed

193

81 women, 17 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 73%
High blood pressure 69%
Osteoporosis 34%
Depression 30%
Ischemic heart disease 23%
Diabetes 16%
Chronic kidney disease 13%
Cancer 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

99 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record